Launch of partnering agreement to strengthen biotech innovators in shared R&D economy – Biotech Investments

• LABCENTRAL, BIOLABS, MBC BIOLABS PARTNER WITH EVOTEC TO SUPPORT BIOTECH INNOVATORS THROUGH CRITICAL INFLECTION POINTS
• AGREEMENT LEVERAGES EVOTEC’S INTEGRATED END-TO-END SHARED R&D PLATFORM TO ENABLE GREATER ACCESS TO INDUSTRY-GRADE CAPABILITIES AND DRUG HUNTING EXPERTISE FOR LIFE SCIENCES AND BIOTECH STARTUPS ACROSS THE GLOBAL LABCENTRAL / BIOLABS / MBC BIOLABS NETWORK
• ALL PARTIES PLAY SYNERGISTIC ROLES IN SUPPORTING AND FOSTERING THE SHARED R&D ECONOMY INNOVATION ECOSYSTEM

Hamburg, Germany, and Cambridge, Mass., USA, 27 September 2023:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO), LabCentral, a launchpad for high-potential life science and biotech start-ups, BioLabs, an international membership based network of shared lab and office facilities, and MBC BioLabs, premier providers of co-working laboratory space, today announced an agreement to boost early-stage innovations through access to Evotec’s leading shared end-to-end R&D platform.

The agreement will empower LabCentral / BioLabs / MBC BioLabs’s network of promising early-stage life science and biotech companies by enhanced access to Evotec’s industry-leading, innovative end-to-end platform and latest technologies for successful drug discovery and development to translate innovative life science research into new, improved ways to treat patients. Through this partnership, Evotec’s team of scientists, business builders and experts will have regular presence on-site across the LabCentral / BioLabs / MBC BioLabs network in the form of hosted educational events and office hours – parts of the efforts towards the joint goal of enhancing success rates of the early-stage companies in the ecosystem.

LabCentral / BioLabs / MBC BioLabs offers laboratory and office spaces for over 400 start-ups comprising approximately 3,500 scientists and entrepreneurs, giving Evotec direct access to promising research of biotech companies across the US, France and Germany.

Dr Matthias Evers, Chief Business Officer of Evotec, commented: “The collaboration with LabCentral / BioLabs / MBC BioLabs is closely aligned with our mission ‘Together for Medicines that Matter’. Providing innovators across a globally recognized life science & biotech network access to our industry-leading end-to-end R&D platform enabling speed, safety, efficiency, and enhanced probabilities of success from bench to bedside, will allow more opportunities to discover and develop life-saving therapies.”

Dr Johannes Fruehauf, Founder and President of BioLabs and LabCentral added: “As a strategic partner across the network of LabCentral and BioLabs facilities, Evotec’s R&D platform will help our residents accelerate their research as we collectively align on a mission to discover and develop new drugs and therapies to improve human health faster, more efficiently and on a global scale.”

Dr Robert Blazej, Director of MBC BioLabs, expressed his excitement about the partnership, stating: “We are thrilled to bring Evotec’s world-leading R&D platform even closer to the companies operating in our San Francisco Bay Area facilities. Our goal has always been to empower brilliant entrepreneurs within a thriving ecosystem that fosters innovation, collaboration, and ultimately, success. Evotec’s shared R&D platform dovetails with our shared lab co-working space, furthering this mission.”

No financial terms of the agreement were disclosed.

ABOUT LABCENTRAL
A private, non-profit institution, LabCentral was founded in 2013 as a launchpad for high potential life-sciences and biotech startups. Operating a total of 225,000 square-feet in the heart of Kendall Square in Cambridge, Mass., LabCentral offers fully permitted laboratory and office space for as many as 100 startups comprising approximately 1,000 scientists and entrepreneurs. More information is available at www.labcentral.org.

ABOUT MBC BIOLABS
MBC BioLabs is a premier life science incubator that provides early-stage biotech companies with the resources and support necessary to thrive. Through its network of state-of-the-art laboratories, industry partnerships, and engaged bioentrepreneur community, MBC BioLabs empowers startups to accelerate their research and propel groundbreaking ideas into transformative therapies. Since opening in 2013, MBC BioLabs has helped launch and grow 290 companies. These companies have brought 153 programs to the clinic, produced 17 approved diagnostics, and raised over $13 billion.

ABOUT EVOTEC SE
Evotec is a life science company with a unique business model that delivers on its mission to discover and develop highly effective therapeutics and make them available to the patients. The Company’s multimodality platform comprises a unique combination of innovative technologies, data and science for the discovery, development, and production of first-in-class and best-in-class pharmaceutical products. Evotec leverages this “Data-driven R&D Autobahn to Cures” for proprietary projects and within a network of partners including all Top 20 Pharma and over 800 biotechnology companies, academic institutions, as well as other healthcare stakeholders. Evotec has strategic activities in a broad range of currently underserved therapeutic areas, including e.g. neurology, oncology, as well as metabolic and infectious diseases. Within these areas of expertise, Evotec aims to create the world-leading co-owned pipeline for innovative therapeutics and has to-date established a portfolio of more than 200 proprietary and co-owned R&D projects from early discovery to clinical development. Evotec operates globally with more than 5,000 highly qualified people. The Company’s 17 sites offer highly synergistic technologies and services and operate as complementary clusters of excellence. For additional information please go to www.evotec.com and follow us on X/Twitter @Evotec and LinkedIn.

FORWARD-LOOKING STATEMENTS
This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec’s securities. Words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “should,” “target,” “would” and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec’s expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

Media Contact Evotec SE:
Gabriele Hansen, SVP Head of Global Corporate Communications, Gabriele.Hansen@evotec.com
Hinnerk Rohwedder, Director of Global Corporate Communications, Hinnerk.Rohwedder@evotec.com

IR Contact Evotec SE:
Volker Braun, SVP Head of Global Investor Relations & ESG, Volker.Braun@evotec.com